All In Biotech

Drug Trial Radar · NCT02820324

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

Last checked: Nov 20, 2026Latest source record: Oct 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 407 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

407

Actual

Start

May 2016

Primary completion

Dec 2016

Study completion Jan 2017

Sponsor

Lead sponsor
Trevena Inc.Industry
Sponsor type
Industry
First posted
Jun 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine administered as needed (PRN) compared with placebo in patients with moderate to severe acute pain after abdominoplasty.

Conditions

  • Acute Pain

Interventions

  • OliceridineDrug

  • PlaceboDrug

  • MorphineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo.Time frame: 24 hours

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Pasadena, California

  • Research Site

    Pasadena, Maryland

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.